This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fallis, R. J. Articles by Lobo, R. A. Search for Related Content PubMed PubMed Citation Articles by Fallis, R. J. Articles by Lobo, R. A.

Stroke, Vol 15, 627-629, Copyright © 1984 by American Heart Association

ARTICLES

A double blind trial of naloxone in the treatment of acute stroke

RJ Fallis, M Fisher and RA Lobo

Naloxone has been reported to have potential benefit in the treatment of stroke. We evaluated the effect of naloxone in a double-blind trial conducted with 15 stroke patients whose deficits ranged from 8 to 60 hours in duration. All but one patient sustained a cerebral infarction. Neurologic function was assessed before and five minutes after each of two injections given to each patient in a double-blind fashion. The injections consisted of naloxone (0.4 mg in 3 patients and 4.0 mg in 12 patients) and saline. Prior to the trial, samples of plasma were obtained for determination of immunoreactive beta-endorphin for each patient. Four patients showed minimal improvement following injection of naloxone, while five patients exhibited a slightly greater improvement following saline injection. There were no significant elevations of plasma beta-endorphin among stroke patients. We conclude that naloxone may not have a significant therapeutic role for stroke in the clinical setting.

This article has been cited by other articles:

				B. Yulug, E. Cam, A. Yildiz, and E. Kilic Buprenorphine Does Not Aggrevate Ischemic Neuronal Injury in Experimental Focal Cerebral Ischemia J Neuropsychiatry Clin Neurosci, August 1, 2007; 19(3): 331 - 334. [Abstract] [Full Text] [PDF]

				Y. Liu, L. Qin, B. C. Wilson, L. An, J.-S. Hong, and B. Liu Inhibition by Naloxone Stereoisomers of beta -Amyloid Peptide (1-42)-induced Superoxide Production in Microglia and Degeneration of Cortical and Mesencephalic Neurons J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1212 - 1219. [Abstract] [Full Text] [PDF]

				B. Liu, J.-W. Jiang, B. C. Wilson, L. Du, S.-N. Yang, J.-Y. Wang, G.-C. Wu, X.-D. Cao, and J.-S. Hong Systemic Infusion of Naloxone Reduces Degeneration of Rat Substantia Nigral Dopaminergic Neurons Induced by Intranigral Injection of Lipopolysaccharide J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 125 - 132. [Abstract] [Full Text]

				W. M. Clark, E. C. Raps, D. C. Tong, and R. E. Kelly Cervene (Nalmefene) in Acute Ischemic Stroke : Final Results of a Phase III Efficacy Study Stroke, June 1, 2000; 31(6): 1234 - 1239. [Abstract] [Full Text] [PDF]

				B. Liu, L. Du, and J.-S. Hong Naloxone Protects Rat Dopaminergic Neurons against Inflammatory Damage through Inhibition of Microglia Activation and Superoxide Generation J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 607 - 617. [Abstract] [Full Text]

				H. Boutin, F. Dauphin, E. T. MacKenzie, P. Jauzac, and R. C. Koehler Differential Time-Course Decreases in Nonselective, µ-, {delta}-, and {kappa}-Opioid Receptors After Focal Cerebral Ischemia in Mice • Editorial Comment Stroke, June 1, 1999; 30(6): 1271 - 1278. [Abstract] [Full Text] [PDF]